Emcure (EMCURE) Q1 FY27 Results: Exports Up 34%, PAT Margin 11.3%

Emcure Pharmaceuticals (EMCURE) - Share price: ₹2,338 (screener.in, 21 November 2026) - Market cap: ₹44,351 crore - P/E: 39.9 (Sun Pharma 36.8, Torrent 82.2, Zydus 26.4 on screener.in) - ROCE: 24.0%

Emcure Pharmaceuticals (EMCURE) grew Q1 FY27 revenue 22.8% to ₹2,580 crore, as international sales rose 34% and profit margin reached 11.3%.

Emcure Q1 FY27 investor presentation: results

Emcure was incorporated in 1981 and is based in Hinjawadi, Pune. It sells medicines for women's health, heart and diabetes care, brain and nerve conditions, HIV (anti-retroviral, or ARV) and biologics. It is listed on NSE and BSE as EMCURE. The numbers are from the investor presentation dated 6 August 2026 for the June 2026 quarter.

₹ crore Q1 FY27 Change on a year ago --------- Revenue from operations 2,580.4 +22.8% Gross profit 1,507.3 margin 58.4% (61.8% a year ago) EBITDA 508.0 +25.8%, margin 19.7% Profit before tax 393.5 +35.3% Profit after tax 292.5 +36.2%, margin 11.3% Adjusted profit after tax 290.9 +33.8%

For all of FY26, revenue was ₹9,203.5 crore, EBITDA ₹1,788.6 crore (19.4% margin) and profit after tax ₹941.3 crore (10.2% margin).

Emcure growth driver: international sales and operating leverage

International business grew 34.2% and is now 58% of revenue, up from about 53% in FY26.

Region Q1 FY27 (₹ crore) Growth on a year ago Share of revenue ------------ India 1,095.3 +10.2% 42% International 1,485.1 +34.2% 58% Europe 536.7 +32.8% 21% Rest of World 521.8 +44.8% 20% Canada 426.6 +24.6% 17%

- Rest of World growth was led by an order book in HIV medicines. The company won more than 15 product approvals across Asia, Africa and Latin America in the quarter and entered 3 new territories. It did not give the order book value. - Rest of World revenue fell 6.1% from the previous quarter, so order-led sales can be uneven. - In Europe, liposomal amphotericin B (a hospital antifungal) is growing. In Canada, one product was approved and two were launched. - India grew 10.2% (12.1% over the previous quarter). Key brands are Orofer XT and Orofer FCM (iron), Tenectase (clot-busting after a heart attack), Metpure (heart and diabetes care) and Poviztra (a lipid-lowering medicine with a new indication for the liver disease MASH).

Is Emcure margin expansion real?

Gross margin fell 3.4 points from 61.8% to 58.4%, because international sales earn less per rupee than Indian sales. EBITDA margin still rose from 19.2% to 19.7%, and profit margin from 10.2% to 11.3%. Management credits productivity gains and operating leverage (costs growing slower than sales). The tax rate was 25.7%, against 26.1% a year ago.

The growth driver in one line Emcure sells more abroad at lower gross margin, but keeps costs under control, so profit still grows faster than sales.

Emcure balance sheet, capex and research

- Net debt was ₹1,102.6 crore at 30 June 2026, which is 0.7 times yearly EBITDA. It was 0.6 times at March 2026 and 0.3 times (₹488.3 crore) at March 2025. The rise comes with the Gennova consolidation and capex. - Return on capital employed (company figure) was 23.4%, against 23.7% at March 2026 and 22.0% at March 2025. - Capex was ₹116.8 crore in the quarter (₹434.2 crore in FY26). - Research spend was ₹90.4 crore, 3.5% of revenue.

How Emcure valuation compares with peers

Company Price (₹) P/E Market cap (₹ crore) ROCE --------------- Emcure Pharmaceuticals 2,338 39.9 44,351 24.0% Sun Pharma 1,885 36.8 4,52,251 20.5% Zydus Lifesciences 1,200 26.4 1,19,700 21.1% Dr Reddy's Labs 1,390 41.5 1,16,119 13.0% Cipla 1,415 36.8 1,14,316 15.5% Torrent Pharma 4,690 82.2 1,78,373 15.2%

Source: screener.in peer table, 21 November 2026 (consolidated). These are the larger listed pharma companies that screener.in groups with Emcure. Emcure trades near Dr Reddy's and Sun Pharma on P/E, with a higher ROCE than all of them. The same table already shows Emcure's September 2026 quarter: sales ₹2,820 crore (up 24.3%) and net profit ₹325 crore (up 33.7%). This article covers the Q1 FY27 presentation only.

What Emcure management plans next

These are management's own forward-looking statements, not promises.

- Numbers: no FY27 revenue, EBITDA or profit target. For India, management expects "continued growth over the full year" as its stronger team and portfolio gain traction. - Leadership: Satish Mehta, Managing Director and CEO, becomes Chairman after the coming AGM. Management links this to its five-year plan. - Gennova: now a wholly-owned subsidiary and the base of the biologics and biosimilars plan. Samit Mehta is its CEO and also Emcure's COO. - HIV prevention: a royalty-free, non-exclusive licence from MSD for alimatravir, a once-monthly oral pre-exposure prevention candidate that is still in late-stage development. - Rest of World: more product approvals and new territories on the back of the order book. - Europe: liposomal amphotericin B and a strong product pipeline for the medium term. - India: better field-force productivity, chronic-segment share and the Poviztra liver-disease indication.

Emcure risks

- International growth is lower in gross margin. If its share grows faster, gross margin may fall faster than costs can fall. - India grows at 10.2%, far below the 34.2% abroad. - Rest of World depends on a lumpy order book. It fell 6.1% over the previous quarter. - About 58% of revenue is earned abroad, so euro, Canadian dollar and US dollar moves change reported rupee revenue. - Net debt more than doubled in 15 months and Gennova must be integrated. - Alimatravir is not yet approved.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://nsearchives.nseindia.com/corporate/EMCURE06082026135536IntimationOfInvestorPresentation.pdf (Emcure Q1 FY27 investor presentation, 6 August 2026)